# A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

> **NCT02170727** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 199 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** DCV/ASV/BMS-791325

## Key facts

- **NCT ID:** NCT02170727
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-26
- **Primary completion:** 2015-06-12
- **Final completion:** 2015-09-09
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2020-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02170727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02170727, "A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02170727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*